Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Lpath Inc (NASDAQ:LPTN)

0.2415
Delayed Data
As of Sep 02
 -0.0085 / -3.40%
Today’s Change
0.18
Today|||52-Week Range
3.80
-91.44%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$7.4M

Company Description

Lpath, Inc. operates as a biotechnology company that focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. The company's product candidate, iSONEP, is currently in a Phase 2 clinical trial to assess the efficacy of iSONEP, given alone or in combination with Lucentis, Avastin, or Eylea in subjects with wet AMD, an ocular disease that often leads to blindness. Its second product candidate, ASONEP, is a monoclonal antibody against sphingosine-1-phosphate that has completed a phase 1 clinical trial in cancer patients. The company's third product candidate, Lpathomab is a monoclonal antibody against lysophosphatidic acid, a key bioactive lipid that has been recognized to be involved in diseases of the central nervous system, fibrosis, ocular disease and cancer. Lpath was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA.

Contact Information

Lpath, Inc.
4025 Sorrento Valley Boulevard
San Diego California 92121
P:(858) 678-0800
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Michael D. LackChief Executive Officer
Gary J. G. AtkinsonChief Financial Officer, Secretary & Senior VP
Gary WoodnuttSenior Vice President-Research
Dario A. PaggiarinoChief Development Officer & Senior Vice President
Roger Allen SabbadiniVice President